# Biocon share price today (Biocon Ltd, NSE: BIOCON)

> Biocon share price today: ₹343.00 at the NSE close on 3 November 2026, down 7.8% in a year. Biocon (NSE: BIOCON) is worth ₹55,867 crore, trades at a P/E of 76.8 and has closed between ₹323.50 and ₹437.20 over the past 52 weeks. > Biocon Ltd's share price has risen faster than its earnings: −7.8% in a year, against −71.8% for earnings per share. BIOCON · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/biocon-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹343.00 (−7.8% in a year)
- P/E: 76.8× (higher than 77% of the last 11 years)
- Revenue (Jun 2026): ₹4,336 Cr (+10.0% on a year ago)
- Profit (Jun 2026): ₹137 Cr (+53.9% on a year ago)
- Operating margin: 20.0% (+1.0 points on a year ago)
- ROCE: 4%, FY26
- ROIC: 3.0%, against a 12.0% cost of capital: −9.0 points

The main question: the share price moved −7.8% in a year while yearly earnings per share moved −71.8%. The difference came from the market paying a higher multiple. ## What is the Biocon share price today? Biocon Ltd's share price was ₹343.00 at the close on 3 November 2026. It has been falling for 3 weeks. That is 11.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹324 and ₹437, and at that close it sat 17% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 15 weeks running. Over the last 11 years the share price moved +324% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 24 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Biocon this quarter? Three changes stood out: profit grew again in the June 2026 quarter, revenue up on a year earlier for 6 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row. 1. Profit grew again in the June 2026 quarter Profit was ₹137 crore, +53.9% on a year earlier (₹89 crore), after 2 quarters of decline. Why: Profit rose because the biosimilar business made more money from recent launches and better market access. From the earnings call on 6 Aug 2026. 2. Revenue up on a year earlier for 6 quarters in a row In the June 2026 quarter revenue was ₹4,336 crore, +10% on a year earlier. Why: Revenue rose because biosimilar sales grew. Next results: check whether Syngene sales improve in the second half as management expects. From the earnings call on 6 Aug 2026. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 7.1% to 8.6% of the company by the September 2026 quarter. ## What are Biocon's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Biocon reported revenue of ₹4,336 crore, up 10.0% from ₹3,942 crore a year earlier, and a profit of ₹137 crore, up 53.9% from ₹89.0 crore. ### Biocon results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹4,336 crore | ₹3,942 crore | +10.0% |
| Profit | ₹137 crore | ₹89.0 crore | +53.9% |
| Earnings per share | ₹0.87 | ₹0.23 | +278.3% |
| Operating margin | 20.0% | 19.0% | +1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Biocon's management discussed these results on a call held on 6 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Biocon share price history? Biocon closed at ₹343.00 on 3 November 2026, down 7.8% from ₹372.10 a year earlier (31 October 2025) and down 1.6% over five years. Its highest weekly close since March 2016 was ₹481.95 on 24 December 2020. ### Biocon share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹323.50 | +6.0% |
| 1 month ago · 1 Oct 2026 | ₹370.70 | −7.5% |
| 6 months ago · 30 Apr 2026 | ₹359.65 | −4.6% |
| 1 year ago · 31 Oct 2025 | ₹372.10 | −7.8% |
| 3 years ago · 3 Nov 2023 | ₹224.50 | +52.8% |
| 5 years ago · 4 Nov 2021 | ₹348.65 | −1.6% |
| 10 years ago · 4 Nov 2016 | ₹146.34 | +134.4% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹80.88 | +324.1% |
| Highest weekly close since March 2016 · 24 Dec 2020 | ₹481.95 | −28.8% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹76.55 | +348.1% |
| 52-week high (weekly close) · 17 Jul 2026 | ₹437.20 | −21.5% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹323.50 | +6.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Biocon? 3 Nov 2026: Biocon closed at ₹343.00, up 6.0% on the week and down 7.5% on the month. 6 Aug 2026: Biocon held its results call for April to June 2026. Management guided: Biosimilars momentum to build progressively through FY27, with meaningful acceleration in H2. ### Earlier

- 3 Jul 2026: ex-date for a dividend of ₹0.50 a share. - Results for April to June 2026: Revenue up 10.0% and profit up 53.9% on a year earlier. ## What dividend does Biocon pay? Biocon paid ₹0.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.15% at the ₹343.00 close on 3 November 2026. The last was a dividend of ₹0.50 a share, ex-date 3 July 2026. ### Biocon dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 3 Jul 2026 | ₹0.50 | Dividend | same day |
| 4 Jul 2025 | ₹0.50 | Dividend | same day |
| 5 Jul 2024 | ₹0.50 | Dividend | same day |
| 7 Jul 2023 | ₹1.50 | Dividend | same day |
| 30 Jun 2022 | ₹0.50 | Dividend | 1 Jul 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Biocon Ltd paid out 21% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Biocon management say on the latest results call? On the call for April to June 2026, held on 6 August 2026, Biocon's management guided: Biosimilars momentum to build progressively through FY27, with meaningful acceleration in H2. > “FY27, we have clearly indicated, is a transition year for Syngene as it navigates the impact of reduced demand from the large biologics client. While revenues are expected to decline in the first half, performance should improve in the second half, resulting in single-digit revenue degrowth in rupee terms for the full year and EBITDA margins returning to the mid-20s.”
> Kiran Mazdar-Shaw, on the call for April to June 2026

### What management guided

- Aflibercept expected to have a good start and build toward H2 as market-access contracts are finalized. - Malaysia insulin second drug-product line supplies to pick up further from July to September 2026. - Generics new launches to scale in subsequent quarters, with profitability expanding through utilization and cost programs. - Biosimilar operating margin to remain in the mid-20s and ramp up through FY27. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4488/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 6 August 2026.)

## What to watch in Biocon's next results? When Biocon reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Biosimilar H2 acceleration and payer-contracted growth - check Aflibercept, Denosumab, Aspart, Ustekinumab, and Bevacizumab contribution. - What to check (from the call)
- Biosimilar H2 acceleration and payer-contracted growth - check Aflibercept, Denosumab, Aspart, Ustekinumab, and Bevacizumab contribution. - Malaysia insulin-line supplies - check whether added capacity converts into sustained insulin revenue and profitability in subsequent prints. - Generics launch scaling and utilization - check whether OPEX, materials, and factory-overhead actions translate into further margin expansion. - Syngene key-client offtake and recovery - check revenue stabilization, margin return, and commercial momentum under the new team. ## Which stock lists is Biocon on? Biocon is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 174](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 57805.61426947129](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Biocon profitable? Biocon Ltd earned ₹137 Cr of net profit in the Jun 2026 quarter, +53.9% on the same quarter a year earlier. Full-year FY26 profit was ₹369 Cr. Over 10 years profit has grown −4.9% a year on average. That is 3.2% of the quarter's revenue. The same quarter a year earlier earned ₹89.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹369 Cr (−74.2% on the year before). Why profit moved: revenue changed +10.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +56.4% and revenue +10.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Biocon make, and is it growing? Biocon Ltd reported ₹4,336 Cr of revenue in the Jun 2026 quarter, +10.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 17.6% a year on average. The last full year, FY26, came in at ₹16,927 Cr. The last four reported quarters add to ₹17,322 Cr. FY26 revenue was ₹16,927 Cr, +10.9% on the year before. Recent pace: the last four quarters grew +10.3% on average, against 17.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.8%, against +8.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −36.4%, against −54.5% a year (accelerating). ## How much of every ₹100 of sales does Biocon keep? Biocon Ltd's operating margin was 20.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 12.0% and 25.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Biocon's profit turning into cash? Over the last 3 years, 291% of Biocon Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,994 Cr of operating cash against ₹369 Cr of profit. After ₹4,959 Cr of spending on assets, free cash was −₹2,965 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 291% of profit came in as cash: the cash cycle got 49 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building. ## Where does Biocon's cash go? Biocon Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 85 days in FY26, down from 134 days in FY21. It spent ₹11,901 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 390 days on average. At FY26 sales of ₹16,927 Cr, each day of that cycle ties up about ₹46.4 Cr, so roughly ₹3,942 Cr is tied up in the business at any time. FY26: customers took 129 days to pay and stock sat for 390 days, about 12.8 months of sales sitting as stock, for a full cycle of 85 days, shorter than FY21's 134. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 390 days. Customers pay about 129 days after that. Suppliers are paid at 434 days. Together that makes the 85-day cycle. Spending on assets: ₹11,901 Cr over the last 3 years, against ₹5,213 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹6,987 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Biocon's P/E ratio, and how does it compare with its own history? Biocon Ltd's P/E is 76.8×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 51.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹3.36. Why the multiple is where it is: over the past year earnings per share moved −71.8% while the price moved −7.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved −0.3% a year; about −4.8% a year came from earnings growth and about +4.5 percentage points from the multiple (the market paying more); over 10 years the price moved +8.9% a year; about +0.0% a year came from earnings growth and about +8.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Biocon business getting better or worse? Biocon Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 3.0%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Biocon earn on its capital? Biocon Ltd earned a ROCE of 4% in FY26. Its return on capital used (ROIC) is 9.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 2.2% net margin and 0.27× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 2.2% net margin × 0.27× asset turnover × 1.86× leverage (assets divided by equity) ≈ 1.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.0% − 12.0% = −9.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Biocon have too much debt? Biocon Ltd has total debt of ₹15,434 Cr against shareholder equity of ₹36,622 Cr as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 0.54 in FY22 to 0.42 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Biocon shareholding pattern? Promoters cut their stake in Biocon Ltd by 16.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 44.7% of the company. Domestic institutions moved +13.9 points over the same period, to 29.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −16.0 points over 8 quarters, to 44.7%; Domestic institutions: +13.9 points over 8 quarters, to 29.2%; Foreign institutions: +3.0 points over 8 quarters, to 8.6%. Why the owners changed: promoters drove it (−16.0 points), with the other side taken by domestic institutions (+13.9 points). They reduced their stake. ## How far is Biocon from balance-sheet trouble? For Biocon Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Biocon rank in its industry? 34.4 out of 100, rank 39 of 44 in Pharma - Formulators, with 96% of the evidence available. Biocon Ltd scores 34.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 39. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.1 + 9.6 + 11.2 + 1.5 = 34.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Biocon compared with? Biocon ranks 39 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 34.4 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. Biocon Ltd this page BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.1/35 · Revenue 9.8% · Profit -36.4% · Operating margin change 1 points · 88% evidence Capital efficiency 9.6/25 · ROCE 3.6% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 78.8× · PEG 0.82 · 100% evidence Relative strength 1.5/20 · Lead over its industry -25% · Lead over NIFTY 500 -5.5% · 1 year -5.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 12.1 + 9.6 + 11.2 + 1.5 = 34.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Biocon in size? Biocon is the 11th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Lupin, Glenmark Pharmaceuticals and Alkem Laboratories. Just below it: Ipca Laboratories, Ajanta Pharma and J B Chemicals & Pharmaceuticals. ### Pharma - Formulators companies close in size

1. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) ₹91,962 crore
2. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) ₹64,875 crore
3. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ₹61,140 crore
4. Biocon Ltd ₹57,333 crore
5. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) ₹48,909 crore
6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹43,846 crore
7. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) ₹38,677 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Nippon Life India Asset Management Ltd](https://www.sectoralpha.in/stocks/nippon-life-india-asset-management-ltd) ₹57,924 crore · Finance - AMC
2. [National Aluminium Company Ltd](https://www.sectoralpha.in/stocks/national-aluminium-company-ltd) ₹57,771 crore · Aluminium
3. Biocon Ltd ₹57,333 crore
4. [Motilal Oswal Financial Services Ltd](https://www.sectoralpha.in/stocks/motilal-oswal-financial-services-ltd) ₹56,797 crore · Finance - Capital Markets - Wealth Management
5. [Sona BLW Precision Forgings Ltd](https://www.sectoralpha.in/stocks/sona-blw-precision-forgings-ltd) ₹55,672 crore · Castings, Forgings & Fastners

## What else do people ask about Biocon? ### What is Biocon's share price today? Biocon Ltd's share price is ₹343.00, −7.8% over the past year. The whole company is worth ₹55,867 Cr on the market. In the last 52 weeks it traded between ₹324 to ₹437; today it is 17% of the way up from the low, 11.4% below its 200-day average (as of 3 November 2026). ### What were Biocon's latest quarterly results? Biocon Ltd reported revenue of ₹4,336 Cr and net profit of ₹137 Cr for the Jun 2026 quarter. Revenue rose 10.0% and profit rose 53.9% compared with a year earlier. Earnings per share were ₹0.87. The operating margin was 20.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Biocon's market cap? Biocon Ltd's market capitalisation is ₹55,867 Cr at a share price of ₹343.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Biocon performing? Biocon Ltd's share price has been falling for 3 weeks. In its latest quarter, revenue rose 10.0% and profit rose 53.9% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 15 weeks running (as of 3 November 2026). ### Will Biocon's share price go up? This page does not forecast Biocon Ltd's share price. What it shows instead: the share price is ₹343.00, and it has been falling for 3 weeks. Its P/E of 76.8× is higher than 77% of its own last 11 years (as of 3 November 2026). ### Does Biocon have too much debt? Biocon Ltd has a moderate amount of debt: its debt is 0.45× its equity, and its operating profit is 4 times its interest bill. FY26 borrowings were ₹15,434 Cr against equity of ₹34,031 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Biocon in its business cycle? Biocon Ltd's FY26 operating margin was 21.0%, against a 13-year range of 12.0% to 25.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Biocon story? The main question: the share price moved −7.8% in a year while yearly earnings per share moved −71.8%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Biocon a stock worth studying right now? What the numbers show: Biocon Ltd's share price has risen faster than its earnings: −7.8% in a year, against −71.8% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Biocon share price forecast for 2026? What management itself guided: Biosimilars momentum to build progressively through FY27, with meaningful acceleration in H2. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.